OXFORD VACMEDIX UK LIMITED

Oxford Vacmedix UK Limited is a bio-pharma company based at the Oxford Science Park, UK, specializing in the development of therapeutic cancer vaccines using the proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr. Shisong Jiang from the University of Oxford’s Department of Oncology. The ROP technology has shown promise in stimulating broad and strong T cell immunity, making it suitable for therapeutic vaccines and diagnostics in cancer and infectious diseases.

The company is focusing on leveraging ROPs to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways, and synergy in combination with other immune oncology (IO) agents. Oxford Vacmedix has established significant collaborations in China through Changzhou Bioscience Group (CBIG), which is using the ROP platform for diagnostics in cancer and infectious diseases.

Oxford Vacmedix is currently concentrating on the development of two lead vaccines: OVM-100, targeting cervical cancer, and OVM-200, an innovative vaccine utilizing survivin to target solid tumors. These vaccines are being tested as single agents and in combination with IO agents to address unmet clinical needs.

In 2018, the company secured a Series A investment of $12.50M from Cancer ROP, a prominent South Korean healthcare institution listed in KOSDAQ, and existing shareholders in China. Oxford Vacmedix is currently seeking Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, both as monotherapy and in combination.